Our findings underscored the critical role of PCSK9 in regulating E-cadherin degradation and suggest that PCSK9 could serve as a novel therapeutic target for ATC, with implications for expanding the therapeutic landscape for this aggressive cancer. This evidence concerns the gene CDH1 and cancer.